US EditionReal-World Study Finds Lower Weight Loss with GLP-1 Drugs Due to Early Discontinuation
- Cleveland Clinic researchers published a June 10, 2025 study in Obesity showing semaglutide and tirzepatide led to less weight loss in real-world US patients from 2021 to 2023.
- The study indicated that patients experienced less average weight loss compared to clinical trials, largely due to more frequent stopping of therapy and the administration of reduced maintenance doses in routine clinical practice.
- Researchers analyzed 7,881 adults with severe obesity, including over 1,300 with pre-diabetes, grouping them by early or late medication discontinuation to assess weight and glycemic outcomes.
- Participants who persisted on high dosages lost up to 18% body weight with tirzepatide, while early discontinuation led to an average 3.6% weight loss, and normal blood sugar normalized in 67.9% who continued treatment.
- The findings suggest that real-world discontinuation and dosage adjustments limit these drugs’ effectiveness for obesity and blood sugar control, especially in pre-diabetic patients, highlighting the importance of adherence.
Insights by Ground AI
Does this summary seem wrong?
17 Articles
17 Articles
All
Left
3
Center
3
Right
3
Evening StandardReposted by 
perspectivemedia.com
perspectivemedia.comWeight loss jabs could be transformative, says outgoing NHS England official
An estimated 1.5 million people are taking weight loss jabs in the UK.
·London, United Kingdom
Read Full Article
Weight loss injections might have lesser impact in real world compared to trials, finds study
A new study published in the Obesity Journal found that anti-obesity injections may have a lesser impact on weight loss in a real-world context compared to clinical trials, as patients tend to discontinue treatment or use a lower maintenance dose. Read on to know more.
·India
Read Full Article
Real-world study finds lower weight loss with GLP-1 drugs due to early discontinuation
A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight loss in a real-world setting because patients discontinue treatment or use lower maintenance dosages.
·United States
Read Full ArticleCoverage Details
Total News Sources17
Leaning Left3Leaning Right3Center3Last UpdatedBias Distribution33% Left, 33% Center, 33% Right
Bias Distribution
- 33% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
33% Right
L 33%
C 33%
R 33%
Factuality
To view factuality data please Upgrade to Premium
